JP2019512002A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019512002A5 JP2019512002A5 JP2018539317A JP2018539317A JP2019512002A5 JP 2019512002 A5 JP2019512002 A5 JP 2019512002A5 JP 2018539317 A JP2018539317 A JP 2018539317A JP 2018539317 A JP2018539317 A JP 2018539317A JP 2019512002 A5 JP2019512002 A5 JP 2019512002A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- antibody
- seq
- acid sequence
- nos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021153453A JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291143P | 2016-02-04 | 2016-02-04 | |
| US62/291,143 | 2016-02-04 | ||
| PCT/US2017/016407 WO2017136659A2 (en) | 2016-02-04 | 2017-02-03 | Humanized anti-cd3 antibodies, conjugates and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153453A Division JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019512002A JP2019512002A (ja) | 2019-05-09 |
| JP2019512002A5 true JP2019512002A5 (enExample) | 2020-03-26 |
| JP6951826B2 JP6951826B2 (ja) | 2021-10-20 |
Family
ID=59501004
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018539317A Active JP6951826B2 (ja) | 2016-02-04 | 2017-02-03 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
| JP2021153453A Pending JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021153453A Pending JP2022023052A (ja) | 2016-02-04 | 2021-09-21 | ヒト化抗ｃｄ３抗体、その複合体、およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US12252534B2 (enExample) |
| EP (1) | EP3411069B1 (enExample) |
| JP (2) | JP6951826B2 (enExample) |
| KR (1) | KR102891788B1 (enExample) |
| CN (1) | CN109069635B (enExample) |
| AU (1) | AU2017213886B2 (enExample) |
| CA (1) | CA3013463C (enExample) |
| ES (1) | ES2992761T3 (enExample) |
| WO (1) | WO2017136659A2 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6501270B2 (ja) | 2013-03-14 | 2019-04-17 | ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ | 標的化剤抗体抱合体およびその使用 |
| EP3411069B1 (en) | 2016-02-04 | 2024-07-10 | The Scripps Research Institute | Humanized anti-cd3 antibodies, conjugates and uses thereof |
| US11472880B2 (en) | 2017-08-14 | 2022-10-18 | Morphosys Ag | Humanized antibodies for CD3 |
| KR101973060B1 (ko) | 2017-10-20 | 2019-04-26 | 주식회사 녹십자 | 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물 |
| EP3844188A1 (en) * | 2018-08-28 | 2021-07-07 | Ambrx, Inc. | Anti-cd3 antibody folate bioconjugates and their uses |
| CN113490690A (zh) * | 2018-12-29 | 2021-10-08 | 南通壹宸生物医药科技有限公司 | 异源二聚体融合蛋白 |
| EP3928790A4 (en) * | 2019-02-22 | 2023-01-11 | Wuhan Yzy Biopharma Co., Ltd. | Cd3 antigen binding fragment and application thereof |
| US20200392230A1 (en) * | 2019-05-14 | 2020-12-17 | Qlb Biotherapeutics | Bispecific anti-cd3 x cd20 antibodies and uses thereof |
| CR20210576A (es) | 2019-05-21 | 2021-12-15 | Novartis Ag | Moléculas de unión a cd19 y usos de las mismas |
| US20220348661A1 (en) * | 2019-09-30 | 2022-11-03 | Harbour Biomed (suzhou) Co., Ltd. | Cd3-targeting antibody, bispecific antibody and use thereof |
| EP4063387A4 (en) * | 2019-11-22 | 2023-08-02 | Nantong Yichen Biopharma. Co. Ltd. | PSMA ANTIBODIES AND ITS USE |
| WO2021173889A1 (en) | 2020-02-26 | 2021-09-02 | Ambrx, Inc. | Uses of anti-cd3 antibody folate bioconjugates |
| TWI827807B (zh) * | 2020-02-26 | 2024-01-01 | 香港商潤俊（中國）有限公司 | 抗cd3抗體葉酸生物共軛物及其用途 |
| IL300256A (en) | 2020-08-25 | 2023-03-01 | Gilead Sciences Inc | Multispecific Antigen Binding Molecules Targeting HIV and Methods of Use |
| CN114853897B (zh) * | 2021-04-15 | 2024-01-26 | 北京大学深圳研究生院 | 抗cd19/cd22/cd3三特异性抗体及用途 |
| MX2024001808A (es) * | 2021-08-09 | 2024-02-29 | Merck Patent Gmbh | Proteinas que desacoplan la citotoxicidad tumoral mediada por celulas t de la liberacion de citoquinas proinflamatorias. |
| WO2023164510A1 (en) | 2022-02-23 | 2023-08-31 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
| CN120603604A (zh) * | 2022-11-18 | 2025-09-05 | Jn生物科学有限责任公司 | 抗cd3抗体 |
| EP4622631A1 (en) | 2022-11-23 | 2025-10-01 | University of Georgia Research Foundation, Inc. | Compositions and methods of use thereof for increasing immune responses |
| KR20240139569A (ko) * | 2023-03-13 | 2024-09-23 | 머스트바이오 주식회사 | 신규한 cd3 결합항체 및 이를 포함한 다중특이 항체 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| CA2103887C (en) | 1991-12-13 | 2005-08-30 | Gary M. Studnicka | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| WO1999029888A1 (en) | 1997-12-05 | 1999-06-17 | The Scripps Research Institute | Humanization of murine antibody |
| US20020142000A1 (en) | 1999-01-15 | 2002-10-03 | Digan Mary Ellen | Anti-CD3 immunotoxins and therapeutic uses therefor |
| US6256533B1 (en) | 1999-06-09 | 2001-07-03 | The Procter & Gamble Company | Apparatus and method for using an intracutaneous microneedle array |
| US7326685B2 (en) | 2001-09-21 | 2008-02-05 | The Administrators Of The Tulane Educational Fund | Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof |
| US7122622B2 (en) | 2002-04-16 | 2006-10-17 | Biosynthema Inc. | Peptide compounds having improved binding affinity to somatostatin receptors |
| DK1629011T3 (da) | 2003-05-31 | 2010-05-03 | Micromet Ag | Humane anti-humane-DC3-bindingsmolekyler |
| CN100477345C (zh) | 2004-03-30 | 2009-04-08 | 株式会社吴羽 | 非水电解质二次电池用负极材料、其制造方法、负极和电池 |
| MXPA06011199A (es) | 2004-03-31 | 2007-04-16 | Genentech Inc | Anticuerpos anti-tgf-beta humanizados. |
| EP1940881B1 (en) | 2005-10-11 | 2016-11-30 | Amgen Research (Munich) GmbH | Compositions comprising cross-species-specific antibodies and uses thereof |
| WO2007058725A2 (en) * | 2005-10-12 | 2007-05-24 | The Regents Of The University Of California | Engineered antibody fragment that irreversibly binds an antigen |
| ES2547554T3 (es) | 2005-11-16 | 2015-10-07 | Ambrx, Inc. | Métodos y composiciones que comprenden aminoácidos no naturales |
| KR101423898B1 (ko) | 2005-12-14 | 2014-07-28 | 암브룩스, 인코포레이티드 | 비-천연 아미노산 및 폴리펩티드를 함유하는 조성물, 비-천연 아미노산 및 폴리펩티드를 포함하는 방법, 및 비-천연 아미노산 및 폴리펩티드의 용도 |
| JP2009522275A (ja) | 2005-12-30 | 2009-06-11 | アンブルックス，インコーポレイテッド | 非天然アミノ酸およびポリペプチドを含んでいる組成物、それらに関する方法、ならびに、それらの使用 |
| EP1974025A4 (en) | 2006-01-19 | 2009-03-11 | Ambrx Inc | NON-NATURAL AMINO ACID POLYPEPTIDES WITH MODULATED IMMUNOGENICITY |
| MX2009006617A (es) | 2006-12-18 | 2009-07-24 | Ambrx Inc | Composiciones que contienen, metodos que involucran y usos de aminoacidos y polipeptidos no naturales. |
| AU2007341997A1 (en) | 2006-12-28 | 2008-07-10 | Ambrx, Inc. | Phenazine and quinoxaline substituted amino acids and polypeptides |
| DK2187965T3 (da) | 2007-08-17 | 2020-01-20 | Purdue Research Foundation | Psma-bindingsligand-linker-konjugater og fremgangsmåder til anvendelse |
| WO2009051974A1 (en) | 2007-10-17 | 2009-04-23 | Nuvelo, Inc. | Antibodes to cll-1 |
| WO2009070642A1 (en) | 2007-11-28 | 2009-06-04 | Medimmune, Llc | Protein formulation |
| SI2291659T1 (sl) | 2008-05-13 | 2016-02-29 | Yale University | Himerične majhne molekule za pridobivanje protiteles za rakave celice |
| MX2011003196A (es) | 2008-09-26 | 2011-04-27 | Ambrx Inc | Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales. |
| WO2012098238A1 (en) * | 2011-01-21 | 2012-07-26 | Novimmune S.A. | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists |
| WO2012142659A1 (en) | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| NZ703939A (en) | 2011-05-21 | 2016-01-29 | Macrogenics Inc | Cd3-binding molecules capable of binding to human and non-human cd3 |
| CN110078788B (zh) | 2011-05-27 | 2021-08-06 | Ambrx 公司 | 含有非天然氨基酸连接的海兔毒素衍生物 |
| CN103702996A (zh) | 2011-05-27 | 2014-04-02 | Ambrx公司 | 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途 |
| US10851178B2 (en) | 2011-10-10 | 2020-12-01 | Xencor, Inc. | Heterodimeric human IgG1 polypeptides with isoelectric point modifications |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| EA201590640A1 (ru) | 2012-09-27 | 2015-11-30 | Мерюс Б.В. | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА КЛАССА IgG В КАЧЕСТВЕ РЕКРУТЕРОВ Т-КЛЕТОК |
| CN104704004B (zh) * | 2012-10-08 | 2019-12-31 | 罗切格利卡特公司 | 包含两个Fab片段的无Fc的抗体及使用方法 |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| US9605084B2 (en) | 2013-03-15 | 2017-03-28 | Xencor, Inc. | Heterodimeric proteins |
| US10131710B2 (en) | 2013-01-14 | 2018-11-20 | Xencor, Inc. | Optimized antibody variable regions |
| KR20150122203A (ko) | 2013-02-26 | 2015-10-30 | 로슈 글리카트 아게 | T 세포 활성화 이중특이적 항원 결합 분자 |
| JP6501270B2 (ja) | 2013-03-14 | 2019-04-17 | ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ | 標的化剤抗体抱合体およびその使用 |
| TW201446804A (zh) | 2013-05-14 | 2014-12-16 | Ambrx公司 | 新穎多肽小分子結合物及其用途 |
| KR102292853B1 (ko) | 2013-06-07 | 2021-08-24 | 리젠 파마슈티컬스 소시에떼 아노님 | 이중 선택적 pi3 델타 및 감마 키나아제 억제제 |
| JP6637415B2 (ja) * | 2013-10-15 | 2020-01-29 | ザ スクリプス リサーチ インスティテュート | キメラ抗原受容体ｔ細胞スイッチおよびその使用 |
| US9493563B2 (en) | 2013-11-04 | 2016-11-15 | Glenmark Pharmaceuticals S.A. | Production of T cell retargeting hetero-dimeric immunoglobulins |
| SG10201809385RA (en) * | 2013-12-17 | 2018-11-29 | Genentech Inc | Anti-cd3 antibodies and methods of use |
| NZ726514A (en) | 2014-05-29 | 2019-01-25 | Macrogenics Inc | Tri-specific binding molecules and methods of use thereof |
| WO2016014974A2 (en) * | 2014-07-25 | 2016-01-28 | Cytomx Therapeutics, Inc. | Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same |
| EP3283113A4 (en) | 2015-04-15 | 2018-12-05 | The California Institute for Biomedical Research | Optimized pne-based chimeric receptor t cell switches and uses thereof |
| EP3411069B1 (en) | 2016-02-04 | 2024-07-10 | The Scripps Research Institute | Humanized anti-cd3 antibodies, conjugates and uses thereof |
-
2017
- 2017-02-03 EP EP17748229.6A patent/EP3411069B1/en active Active
- 2017-02-03 US US16/074,600 patent/US12252534B2/en active Active
- 2017-02-03 CN CN201780024266.1A patent/CN109069635B/zh active Active
- 2017-02-03 JP JP2018539317A patent/JP6951826B2/ja active Active
- 2017-02-03 KR KR1020187025472A patent/KR102891788B1/ko active Active
- 2017-02-03 AU AU2017213886A patent/AU2017213886B2/en active Active
- 2017-02-03 CA CA3013463A patent/CA3013463C/en active Active
- 2017-02-03 ES ES17748229T patent/ES2992761T3/es active Active
- 2017-02-03 WO PCT/US2017/016407 patent/WO2017136659A2/en not_active Ceased
-
2021
- 2021-09-21 JP JP2021153453A patent/JP2022023052A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019512002A5 (enExample) | ||
| AR111361A1 (es) | Anticuerpos biespecíficos de unión específica a pd1 y lag3 | |
| WO2015138907A3 (en) | Hybrid immunoglobulin containing non-peptidyl linkage | |
| CY1120414T1 (el) | Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους | |
| FI3683235T3 (fi) | Anti-IL-33-vasta-aineita ja niiden käyttöjä | |
| CY1114851T1 (el) | Il-1βητα δεσμευτικα αντισωματα και θραυσματα αυτων | |
| JP2013530929A5 (enExample) | ||
| AR095980A1 (es) | Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización | |
| AR109355A2 (es) | Moléculas de unión al receptor ox40 humano | |
| RU2015147300A (ru) | Гуманизированные антитела к cxcr5, их производные и их применение | |
| FI3596125T3 (fi) | Anti-PAR2-vasta-aineita ja niiden käyttöjä | |
| CY1118008T1 (el) | Πρωτεϊνες δεσμευσης ετεροδιμερους και χρησεις αυτων | |
| AR077088A1 (es) | Proteinas biespecificas de union a antigeno | |
| JP2017518083A (ja) | ｉｎ ｖｉｖｏでの非共有結合的連結のための方法および組成物 | |
| JP2016538240A5 (enExample) | ||
| JP2005120106A5 (enExample) | ||
| AR110755A1 (es) | Anticuerpos dirigidos a hueso | |
| CN102838663B (zh) | 定点突变和定点修饰的病毒膜蛋白、其制备方法及其应用 | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| Okochi et al. | Array-based rational design of short peptide probe-derived from an anti-TNT monoclonal antibody | |
| PE20220763A1 (es) | Materiales y metodos para modular la inmunidad mediada por celulas t | |
| JP2013538791A5 (enExample) | ||
| ECSP18084153A (es) | Anticuerpos anti-BASIGIN humanizados y uso de los mismos | |
| WO2019104155A3 (en) | Chemical probe-dependent evaluation of protein activity and uses thereof | |
| RU2015154792A (ru) | Выделенный антиген лейкоцидина Staphylococcus aureus, антитело, специфически связывающееся с субъединицей LukGH и способ определения связывания или токсичности двухкомпонентного цитолизина LukGH Staphylococcus aureus |